The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +1412.86%. As of the latest data, the price of $52.967 sits at approximately 99.6% of its 52-week high of $53.19, indicating the stock is trading at its absolute peak. This positioning near the highs reflects extreme momentum but also suggests the stock is highly extended and vulnerable to any negative news or profit-taking. Recent momentum shows a deceleration from the explosive longer-term trend; the 1-month price change is a modest +0.44%, significantly underperforming the S&P 500's +11.37% gain, while the 3-month return of +37.46% remains strong. This divergence, where short-term momentum lags both the long-term trend and the broader market, could signal a consolidation phase or a loss of upward thrust following the acquisition-driven rally. Key technical levels are clear: immediate resistance is the 52-week high at $53.19, while support is far below at the 52-week low of $2.655. A breakout above $53.19 would signal a continuation of the bullish trend, though limited headroom exists, while a breakdown below recent consolidation near $52 would suggest a deeper pullback. The stock's beta of -0.38 indicates it has exhibited low and inverse correlation to the market over the measured period, which is atypical for a biotech and likely reflects idiosyncratic, event-driven price action centered on M&A speculation.

As a pre-revenue clinical-stage biotech, Terns has no product sales, with quarterly revenue consistently reported as $0. The company's financials are entirely defined by its R&D burn rate, as it advances its pipeline. The most recent quarterly net income was -$23.57 million, with an EPS of -$0.24. Profitability metrics are all negative or zero, including a gross margin of 0% and a net margin of 0%, which is standard for a company in this development phase. The balance sheet and cash flow are critical: the company reported a robust cash position of $524.75 million at the end of Q4 2025, bolstered by significant financing activities including $706.39 million from common stock issuance. The debt-to-equity ratio is negligible at 0.0009, indicating a virtually debt-free capital structure. However, operating and free cash flow are deeply negative, with quarterly operating cash flow at -$19.08 million and TTM free cash flow at -$82.18 million. The current ratio is exceptionally high at 62.41, showing ample liquidity to fund operations in the near term without the need for immediate additional financing, assuming the acquisition does not proceed.